About us

We are building the next-generation of painkillers

With over 25 years of experience in pain research and the pharmaceutical industry, we are dedicated to researching new treatments for serious diseases in areas with significant unmet medical needs and to ensuring these solutions reach the patients who need them most.

Our vision

At Dolinnov, we believe the answer is not in blocking ion channels but in modulating the ion pump that drives neuronal hyperexcitability.

Our mission is to bring the first Precision Pump Modulator to patients suffering from extreme chronic pain and prove that it can be done.

Precision medicine
Broad Potential
application
Outstanding Proof
of Efficacy

Our operating team

Grégoire Serra
Grégoire Serra
CEO & Co-founder
Grégoire Serra
CEO & Co-founder

Grégoire Serra combines dual expertise in science and law to navigate research, innovation, and regulation. With experience in pharma partnerships, technology transfer, and IP, he drives strategic collaborations and accelerates financing to bring academic projects to the clinic.

Dr. Stéphanie
Ventéo
Dr. Stéphanie
Ventéo
Principal Scientific founder
Dr. Stéphanie
Ventéo
Principal Scientific founder

Dr. Stéphanie Ventéo holds a PhD in Neuroscience and is a Research Engineer at INSERM, leading her group at the Institute for Neurosciences of Montpellier. With 25+ years dedicated to the physiology and pathology of the somatosensory system, her expertise drives groundbreaking advances in chronic pain management.

Jean Philippe Annereau
Jean Philippe Annereau
CSO & Co-founder
Jean Philippe Annereau
CSO & Co-founder

Dr. Jean-Philippe Annereau, PhD from École Polytechnique, brings 20+ years in pharma, focused on oncology and rare diseases. CEO of Medetia Pharmaceuticals and former CEO of Alexion R&D France, he has a strong track record in innovation. At Dolinnov, he shapes R&D strategy to accelerate new pain management solutions.

An innovation-driven team

World-class and experienced team with recognized 
KOL Pain Management given its experience in the development of pain treatments

What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.

Jean-Philippe Annereau, CSO & Co-Founder

It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.

Dr. Stéphanie Venteo, Principal Scientific founder

Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.

Gregoire Serra, CEO & Co-founder

Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.

Alix Pradère, Investor

Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.

Gregoire Serra, CEO & Co-founder

It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.

Dr. Stéphanie Venteo, CSO & Co-founder

What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.

Jean-Philippe Annereau, R&D Strategy & Co-founder

Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.

Alix Pradère, Investor
Trust in our project
Trust in our project
Trust in our project
Trust in our project
+3M€ deployed

already deployed on this project

Partners supporting the project

Join the pain management revolution!

Contact us